Gastric cancer (GC) remains a major public health problem throughout the world. In this study, we investigated the involvement of a new member of cyclin-dependent kinases, cyclin-dependent kinase-like 2 (CDKL2) in tumor progression, and in the prognosis of human GC.
The patient cohort in this study consisted of 151 GC cases, documenting pathologic and clinical factors, as well as clinical outcomes. Immunohistochemistry and immunoblotting were employed to examine the CDKL2 expression in 151 pairs of normal and GC tissues and 5 gastric cells. Based on the expression of CDKL2, two GC cell with low CDKL2 level was chosen for CDKL2 overexpression. The effect of CDKL2 overexpression on the growth of CDKL2-manupulated GC cells was examined.
Downregulation of CDKL2 protein was observed in 83 patients and was significantly correlated with Lauren classification, staging, degree of differentiation, and poor disease-free survival. Univariate Cox regression analysis showed that loss of CDKL2 is a prognostic marker for GC. Furthermore, CDKL2 expression was suppressed in several GC cells. In vitro experiments indicated that CDKL2 overexpression inhibited GC cell growth.
This study suggests that loss of CDKL2 can be a useful marker for predicting the outcome of GC patients.
Clinical trial identification
Legal entity responsible for the study
The institutional review board at Chi-Mei Medical Center
Chi-Mei Medical Center
All authors have declared no conflicts of interest.